Bicyclic pyrimidine compounds as potent IRAK4 inhibitors.

ATOM RECORD CONTAINS RESIDUAL B FACTORS ONLY from an older version of REFMAC

Interleukin-1 receptor-associated kinase 4

IRAK-4,Renal carcinoma antigen NY-REN-64

The purified protein was used in crystallisation trials employing both, a standard screen with approximately 1200 different conditions, as well as crystallisation conditions identified using literature data. Conditions initially obtained have been optimised using standard strategies, systematically varying parameters critically influencing crystallisation, such as temperature, protein concentration, drop ratio, and others. These conditions were also refined by systematically varying pH or precipitant concentrations.

kinase inhibitor, IRAK4, pyrimidine, ATP binding, PROTEIN BINDING, SIGNALING PROTEIN